{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-025464","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.537552+00:00","generated_at":"2026-05-15T16:57:42.501963+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers","bullets":["24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.","No unexpected safety signals or serious immune-related adverse events observed in 25 evaluable patients.","Investigator-initiated trial by University of Pittsburgh; full results expected at upcoming international cancer conference.","Study evaluated LYMPHIR (denileukin diftitox-cxdl) + pembrolizumab in relapsed/refractory ovarian and endometrial cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-025464","json":"https://secwatch.observer/filing/0001213900-26-025464.json","markdown":"https://secwatch.observer/filing/0001213900-26-025464.md","text":"https://secwatch.observer/filing/0001213900-26-025464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/0001213900-26-025464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:57:42.501963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}